DIAGNOSTIC METHOD OF CLINICALLY SIGNIFICANT PROSTATE CANCER Russian patent published in 2019 - IPC A61B5/55 A61B10/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, urology, and roentgen diagnostics, and can be used to diagnose clinically significant prostate cancer. Multiparametric magnetic resonance imaging of the pelvic organs, a standard 12-core biopsy of the prostate gland is carried out before the prostate biopsy. Additionally three-dimensional pulse sequence 3D-Cube performed with magnetic resonance imaging. Process the received MR data at the GEAW 4.7 VolumeShare7 workstation in the reformat and readyview programs. Mark layers of the prostate gland, urethra, seminal vesicles and lesions suspicious of the presence of clinically significant cancer, each of which is marked into a separate figure and saved as a 3D model in STL format. Combine the obtained models in real volume on a personal computer in the Meshlab 2016 program into a single 3D model. In the final 3D model, the prostate gland is labeled transparent, the urethra and the seminal vesicles in white. And foci depending on the scores as per PiRads v2.0 are labeled as follows: 3 points – green, 4 points – yellow and 5 points – red. Model is saved and used as a visual three-dimensional image of the volume, size and localization of prostate foci. Measure the distance from any part – the urethra, capsules, apex, base, anterior section of the prostate – to the focus. On the basis of a visual analysis of a spatial 3D model, in addition to the standard 12-core biopsy, 2 additional injections are made in each prostate gland graduated according to the PiRads scale ≥ 3.

EFFECT: method provides improved diagnostics of clinically significant prostate cancer by labeling and measuring in a single 3D model in the STL format, obtained by multiparameter magnetic resonance imaging of pelvic organs, and in addition to the standard 12-core biopsy, 2 additional injections in each prostate focus.

1 cl, 2 ex